1228012-18-7
Chemical Structure
CC214-2
- CAS No.: 1228012-18-7
- Formula:C20H25N5O3
- Molecular Weight:383.44
IUPAC Name: 5-nitrobenzo[b]thiophen-3(2H)-one 1,1-dioxide
InChIKey: UWUPKVZQISLSSA-UHFFFAOYSA-N
SMILES: O=C1N=C2NC=C(C3=CC=C(C(C)(C)O)N=C3)N=C2N(CC4CCOCC4)C1
Biological Activity: CC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473). CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin (HY-10219)-resistant signaling and the growth of glioblastomas in vitro and in vivo[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CC214-2 | 98.41% | CC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473). CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin (HY-10219)-resistant signaling and the growth of glioblastomas in vitro and in vivo. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.46
HY-16962CC-115 -
Similarity Score 0.46
HY-16962ACC-115 hydrochloride -
Similarity Score 0.41
HY-112198AZ31 -
Similarity Score 0.39
HY-146662HPGDS inhibitor 3 -
Similarity Score 0.39
HY-161723LH2-051 -
Similarity Score 0.39
HY-145694CDK5-IN-3 -
Similarity Score 0.39
HY-125538Deoxybrevianamide E -
Similarity Score 0.39
HY-50669MK-0812 -
Similarity Score 0.38
HY-B1017Molindone (hydrochloride) -
Explore the MedChemAI to find more analogs
References
- [1]. Gini B, et al. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. Clin Cancer Res. 2013 Oct 15;19(20):5722-32. [Content Brief]
- [2]. Tasneen R, et al. Dual mTORC1/mTORC2 Inhibition as a Host-Directed Therapeutic Target in Pathologically Distinct Mouse Models of Tuberculosis. Antimicrob Agents Chemother. 2021;65(7):e0025321. [Content Brief]
